ERAS for Gastric Cancer Patients After NACT
Short- and Long-term Outcomes Following Perioperative ERAS Management in Patients Undergoing Minimally Invasive Radical Gastrectomy After Neoadjuvant Chemotherapy: A Single-center Retrospective Propensity Score Matching Cohort Study
1 other identifier
observational
252
1 country
1
Brief Summary
Background: Gastric cancer patients receiving neoadjuvant chemotherapy (NACT) are more vulnerable to perioperative stress. Enhanced recovery after surgery (ERAS) is widely used in surgical patients aiming at reducing stress responses. However, whether this approach is safe and feasible for gastric cancer patients received minimally invasive radical gastrectomy after NACT remained determined. So, the objective of this study is to investigate the effects of ERAS for this special group of gastric cancer patients. Materials and Methods: The data of gastric cancer patients who underwent minimally invasive radical gastrectomy after NACT were collected in this retrospective cohort study. Patients were divided into an ERAS group and a conventional group based on whether they received perioperative ERAS management. Propensity score matching was conducted to eliminate bias. Pre- and postoperative inflammatory and nutritional marker levels, postoperative complications, recovery indices and 3-year OS and RFS were observed.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2023
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2024
CompletedFirst Submitted
Initial submission to the registry
April 9, 2024
CompletedFirst Posted
Study publicly available on registry
April 15, 2024
CompletedApril 15, 2024
April 1, 2024
6 months
April 9, 2024
April 11, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
postoperative infectious complications
The primary outcome was the incidence of postoperative infectious complications, which were defined as bacterial infections within 30 d after surgery. The diagnosis of infectious complications was based on fever (≥38°C), elevation of C-reactive protein (CRP), specific clinical symptoms of infection, and positive bacterial culture.
up tp 30 days after surgery
Secondary Outcomes (4)
postoperative recovery parameter
up tp 30 days after surgery
blood test result
Postoperative, on postoperative day 1, 3 and 5
3-year overall survival
3 years
3-years recurrence-free survival
3 years
Study Arms (2)
ERAS group
Conventional group
Interventions
ERAS is a comprehensive perioperative interventions, including preoperative patient education, prehabilitation, nutritional support, minimally invasive surgery and other methods, can reduce surgical stress and promote patient recovery
Eligibility Criteria
From January 2015 to October 2020, the data of 390 gastric cancer patients who underwent laparoscopic or robotic minimally invasive radical gastrectomy after NACT at the Department of Gastrointestinal Surgery, the Affiliated Hospital of Qingdao University, were collected and divided into ERAS group and conventional group according to whether they received perioperative ERAS pathway management.
You may qualify if:
- gastric adenocarcinoma confirmed by histopathology,
- received 2 to 4 cycles of NACT before surgery,
- minimally invasive (DaVinci or laparoscopy) radical gastrectomy with D2 lymph node dissection
You may not qualify if:
- conversion to open surgery due to intraoperative difficulties or uncontrolled complications (for example, intraoperative massive bleeding),
- inability to complete the planned preoperative chemotherapy,
- infeasibility of performing radical gastrectomy during surgery
- ERAS item implementation rate less than 60%
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Gastrointestinal Surgery, Qingdao University Affiliated Hospital
Qingdao, Shandong, 266000, China
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Prof.
Study Record Dates
First Submitted
April 9, 2024
First Posted
April 15, 2024
Study Start
October 1, 2023
Primary Completion
April 1, 2024
Study Completion
April 1, 2024
Last Updated
April 15, 2024
Record last verified: 2024-04